• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [19081 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brivaracetam (epilepsy in children [aged 2 to < 4 years]) - Benefit assessment according to §35a Social Code Book V]
2022     Health Information and Quality Authority (HIQA) Descriptive analysis of COVID-19 epidemiological indicators and associated contextual factors in European countries
2022     Agency for Care Effectiveness (ACE) Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vedolizumab (antibiotic refractory chronic pouchitis) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lorlatinib (NSCLC) - benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Daratumumab-based regimens for newly diagnosed multiple myeloma
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tepotinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2022     Agency for Care Effectiveness (ACE) Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abrocitinib (atopic dermatitis) - Addendum to Commission A22-06]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: circulating tumour DNA (liquid biopsy)-based EGFR exon 20 T790M mutation detection in advanced non-small cell lung cancer after previous EGFR-directed therapy]
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for chronic lymphocytic leukaemia
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stent retriever for the treatment of cerebral artery vasospasm following subarachnoid haemorrhage - Addendum to Commission H21-10]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Post covid - treatment and rehabilitation. Living review.
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: profile of individuals with a history of cancer infected with SARS-CoV-2 during the first two waves of the pandemic]
2022     Agency for Care Effectiveness (ACE) Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality in revision surgery (knee)]
2022     Norwegian Institute of Public Health (NIPH) [Operating room ventilation: a health technology assessment]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avapritinib (advanced systemic mastocytosis) - Assessment according to §35a (para. 1., sentence 11)]
2022     Norwegian Institute of Public Health (NIPH) Molecular tests for detection of PIK3CA mutations in men and postmenopausal women with HR+/HER2–, locally advanced or metastatic breast cancer: a health technology assessment
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dolutegravir (HIV) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anifrolumab (systemic lupus erythematosus) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Technology Assessment programme Health-Related Quality of Life in two treatment pathways for newly diagnosed open angle glaucoma and ocular hypertension: an unmasked, multi-centre, randomised controlled trial of initial selective laser trabeculoplasty versus conventional medical therapy
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: immunoglobulin shortage: alternative treatments to nonspecific human immunoglobulins]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Psycho- and sociotherapeutic interventions: Adults - Evidence report on the S3 guideline "Cannabis-related disorders"]
2022     Center for Evidence-based Practice (CEP) Breast cancer risk assessment tools
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Voretigene neparvovec (inherited retinal dystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Center for Evidence-based Practice (CEP) Testosterone reference ranges for gender diverse individuals
2022     Center for Evidence-based Practice (CEP) Structured screening questionnaires for alcohol misuse/alcohol use disorders
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Home-based oral nutritional supplements in cancer patients who require modification of the usual ordinary diet due to mucositis]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: updated recommendations for adjusting antidiabetic medication in type 2 diabetes]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Home-based oral nutritional supplements in cancer patients with moderate-severe malnutrition undergoing active treatment]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating pharmacological treatment for oropharyngeal mucositis in a patient receiving cancer therapy]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of age limits in the mammography screening programme]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: intravenous iron therapy in adults]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Second addendum to commission H21-14]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of the relevance of newborn screening for severe combined immunodeficiency SCID]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Casirivimab/imdevimab (post-exposure prophylaxis of COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022     Center for Evidence-based Practice (CEP) Clinical utility of inpatient fall risk assessment
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §Social Code Book V]
2022     NIHR Health Technology Assessment programme HALT-IT trial (Haemorrhage Alleviation with Tranexamic acid Intestinal System), a large randomised placebo controlled trial among patients with acute gastrointestinal haemorrhage of the effects of tranexamic acid on death and transfusion requirement
2022     Norwegian Institute of Public Health (NIPH) [Surgery for degenerative rotator cuff tears - Protocol for Health Technology Assessment - project description]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of insulin pump systems for type 1 diabetes patients]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Doravirine (HIV infection in adolescents) - Benefit assessment according to §35a Social Code Book V]
2022     Norwegian Institute of Public Health (NIPH) Tests for the detection of NTRK gene fusions in patients with locally advanced or metastatic solid tumours
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: relevance of the prerequisite of the use of an immunosuppressant drug for the coverage of biologic agents (gastroenterology and dermatology)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brolucizumab (visual impairment due to diabetic macular oedema) - Benefit assessment according to §35a Social Code Book V]
2022     Austrian Institute for Health Technology Assessment (AIHTA) CAR-T cell-therapies in development, update 2022
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries
2022     NIHR Health Technology Assessment programme Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework
2022     Austrian Institute for Health Technology Assessment (AIHTA) [Telemonitoring in Austrian diabetes care: a systematic analysis of evaluation methodologies]
2022     NIHR Health Services and Delivery Research programme Components of interventions to reduce restrictive practices with children and young people in institutional settings: the Contrast systematic mapping review
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V]
2022     NIHR Health Services and Delivery Research programme Assessment and management pathways of older adults with mild cognitive impairment: descriptive review and critical interpretive synthesis
2022     Health Information and Quality Authority (HIQA) Health technology assessment of metabolic surgery for the treatment of comorbid type 2 diabetes and obesity
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tebentafusp (uveal melanoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institute for Clinical and Economic Review (ICER) Betibeglogene autotemcel for beta thalassemia: effectiveness and value
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ceftazidime/avibactam (bacterial infection) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institute for Clinical and Economic Review (ICER) Special assessment of outpatient treatments for COVID-19
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Imipenem/cilastatin/relebactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2022     Institute for Clinical and Economic Review (ICER) Tirzepatide for type 2 diabetes
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - children and adolescents]
2022     NIHR Health Technology Assessment programme Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for obesity - adults]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V]
2022     Ontario Health Transcatheter valve-in-valve implantation for degenerated mitral or tricuspid bioprosthetic valves: a health technology assessment
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Empagliflozin (heart failure and preserved ejection fraction) - Addendum to Commission A22-39]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: high-dose vitamin C injections for cancer patients in Quebec]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (follicular lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Setmelanotide (obesity and control of hunger in POMC, PCSK1 or LEPR deficiency obesity) - Assessment according to §35a (para. 1, sentence 11) Social Code Book VAuftraggeber: G-BA]
2022     Ontario Health Molecular testing for thyroid nodules with atypical cells of indeterminate significance
2022     NIHR Health Technology Assessment programme Outcome after selective early closure of ductus arteriosus in extremely preterm babies (Baby-OSCAR trial)
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment of hyperemesis (severe nausea during pregnancy)
2022     Austrian Institute for Health Technology Assessment (AIHTA) Wearable cardioverter-defibrillator (WCD) therapy for primary and secondary prevention of sudden cardiac arrest. Update 2022
2022     Austrian Institute for Health Technology Assessment (AIHTA) Long COVID care pathways and structures: an updated scoping review
2022     NIHR Health Technology Assessment programme Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis
2022     NIHR Health Services and Delivery Research programme Perioperative exercise programmes to promote physical activity in the medium to long term: systematic review and qualitative research
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with physical disabilities using rehabilitation services]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: risks of hospitalization and death related to COVID-19 in people with intellectual disabilities (ID) or autism spectrum disorder (ASD)]
2022     NIHR Health Technology Assessment programme A randomised controlled trial of a protease inhibitor monotherapy versus continuing combination antiretroviral therapy for HIV-1 infected patients previously established on a dual nucleoside and non-nucleoside combination regimen
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of microsurgery for the prevention and treatment of cancer-related lymphedema]
2022     Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness, safety, and economic assessment of mass screening for hepatitis C. Systematic review]
2021     Scottish Medicines Consortium (SMC) Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021     Health Information and Quality Authority (HIQA) Rapid review of public health guidance on protective measures for vulnerable groups in the context of COVID-19
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Scottish Medicines Consortium (SMC) Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021     Health Technology Wales (HTW) Strategies for Relatives (START) intervention to improve the mental health of carers of people with dementia
2021     Health Information and Quality Authority (HIQA) Rolling summary of the evidence in relation to the Omicron (B.1.1.529) variant
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial carcinoma first line treatment) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     NIHR Health Technology Assessment programme A comparison of general anaesthesia versus awake-regional anaesthesia in infancy: an international, multicentre, randomised controlled equivalence trial; the GAS study
2021     Belgian Health Care Knowledge Centre (KCE) Remote monitoring of patients with cardiovascular implantable electronic devices: a health technology assessment (update of the KCE Report 136)
2021     Health Information and Quality Authority (HIQA) Use of respirator masks by persons who are at higher risk from COVID-19
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     Health Council of the Netherlands Gezondheidsraad (GR) [Influenza vaccination: review of indications]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Rebinyn (nonacog beta pegol) – Type B hemophilia (re-evaluation)]
2021     Health Information and Quality Authority (HIQA) Rapid review of public health guidance for residential care facilities in the context of COVID-19
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2021     Austrian Institute for Health Technology Assessment (AIHTA) Long COVID care pathways: a systematic review